ZA200905472B - Pharmaceutical compositions comprising a calcilytic agent - Google Patents

Pharmaceutical compositions comprising a calcilytic agent

Info

Publication number
ZA200905472B
ZA200905472B ZA200905472A ZA200905472A ZA200905472B ZA 200905472 B ZA200905472 B ZA 200905472B ZA 200905472 A ZA200905472 A ZA 200905472A ZA 200905472 A ZA200905472 A ZA 200905472A ZA 200905472 B ZA200905472 B ZA 200905472B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical compositions
calcilytic agent
calcilytic
agent
pharmaceutical
Prior art date
Application number
ZA200905472A
Other languages
English (en)
Inventor
Thomas Buhl
Elisabete Goncalves
Oscar Kalb
Lorenz Meinel
Sibylle Reidemeister
Agnes Taillardat
Leo Widler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38016483&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200905472(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200905472B publication Critical patent/ZA200905472B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200905472A 2007-03-02 2009-08-05 Pharmaceutical compositions comprising a calcilytic agent ZA200905472B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07103365A EP1964548A1 (en) 2007-03-02 2007-03-02 Pharmaceutical compositions comprising a calcilytic agent

Publications (1)

Publication Number Publication Date
ZA200905472B true ZA200905472B (en) 2010-04-28

Family

ID=38016483

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200905472A ZA200905472B (en) 2007-03-02 2009-08-05 Pharmaceutical compositions comprising a calcilytic agent

Country Status (20)

Country Link
US (1) US20100022565A1 (xx)
EP (2) EP1964548A1 (xx)
JP (1) JP2010520179A (xx)
KR (1) KR20090125245A (xx)
CN (1) CN101621993A (xx)
AR (1) AR065564A1 (xx)
AU (1) AU2008223876A1 (xx)
CA (1) CA2678794A1 (xx)
CL (1) CL2008000617A1 (xx)
CO (1) CO6210808A2 (xx)
EC (1) ECSP099611A (xx)
GT (1) GT200900235A (xx)
IL (1) IL200274A0 (xx)
MA (1) MA31201B1 (xx)
MX (1) MX2009009343A (xx)
PE (1) PE20081794A1 (xx)
TN (1) TN2009000358A1 (xx)
TW (1) TW200843762A (xx)
WO (1) WO2008107390A1 (xx)
ZA (1) ZA200905472B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606426D0 (en) * 2006-03-30 2006-05-10 Novartis Ag Benzimidazole derivatives
EP2079739A2 (en) 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
EP3004224B1 (en) * 2013-06-04 2022-01-26 Monosol, LLC Water-soluble film sealing solutions, related methods, and related articles
EP3458015A4 (en) * 2016-05-20 2020-02-19 Azure Biotech, Inc. VAGINAL ADMINISTRATION SYSTEMS WITH SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM) AND USES THEREOF
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
KR102220255B1 (ko) * 2019-08-13 2021-02-26 동국대학교 산학협력단 수술 후 부갑상선기능저하증 개선 또는 치료용 약학 조성물 및 이를 이용한 치료 방법
WO2021029517A1 (en) * 2019-08-13 2021-02-18 Dongguk University Industry-Academic Cooperation Foundation Pharmaceutical composition for improving or treating post-surgical hypoparathyroidism and treatment method using the same
KR20230106582A (ko) * 2020-08-04 2023-07-13 캘시리틱스 테라퓨틱스, 인코포레이티드 트리페닐 칼실리틱 화합물의 제형

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202261B2 (en) * 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
PE20001456A1 (es) * 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
AU2003291761A1 (en) * 2002-11-04 2004-06-07 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics

Also Published As

Publication number Publication date
EP2124893A1 (en) 2009-12-02
WO2008107390A1 (en) 2008-09-12
KR20090125245A (ko) 2009-12-04
ECSP099611A (es) 2009-10-30
TN2009000358A1 (en) 2010-12-31
CL2008000617A1 (es) 2008-09-12
CN101621993A (zh) 2010-01-06
JP2010520179A (ja) 2010-06-10
GT200900235A (es) 2010-03-15
US20100022565A1 (en) 2010-01-28
IL200274A0 (en) 2010-04-29
EP1964548A1 (en) 2008-09-03
TW200843762A (en) 2008-11-16
CA2678794A1 (en) 2008-09-12
AU2008223876A1 (en) 2008-09-12
MA31201B1 (fr) 2010-02-01
AR065564A1 (es) 2009-06-17
CO6210808A2 (es) 2010-10-20
MX2009009343A (es) 2009-09-11
PE20081794A1 (es) 2009-01-09

Similar Documents

Publication Publication Date Title
IL247741A0 (en) pharmaceutical preparations
ZA200904935B (en) Benefit agent delivery compositions
GB2450753B (en) New Pharmaceutical formulation
EP2001498A4 (en) PHARMACEUTICAL COMPOSITIONS
IL194176A0 (en) Pharmaceutical compositions
GB0625322D0 (en) Pharmaceutical compositions
HK1138732A1 (en) Pharmaceutical compositions
EP2222313A4 (en) PHARMACEUTICAL COMPOSITIONS
AP2008004673A0 (en) Stabilized pharmaceutical compositions comprising fesoterodine
IL200274A0 (en) Pharmaceutical compositions comprising a calcilytic agent
GB0610322D0 (en) Novel pharmaceutical compositions
GB0608724D0 (en) Novel Pharmaceutical Compositions
GB0712389D0 (en) A Pharmaceutical composition
EP2146695A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2120898A4 (en) CALCILYTIC COMPOUNDS
GB0709811D0 (en) Pharmaceutical compositions
GB0707127D0 (en) Pharmaceutical compositions
GB0712454D0 (en) Pharmaceutical compositions
GB2454923B (en) Pharmaceutical compositions
IL201394A0 (en) Niacin - based pharmaceutical compositions
EP2204173A4 (en) PHARMACEUTICAL COMPOSITION HAVING ANTIDIABETIC EFFECT
GB0622964D0 (en) Pharmaceutical compositions
GB0609941D0 (en) Pharmaceutical compositions
GB0621623D0 (en) Pharmaceutical compositions
HU0600938D0 (en) Pharmaceutical compositions